Ohio manufacturer nears deal for extraction technology
The Ohio-based PAO Group (PAOG) is one step closer to moving RespRX to market for the treatment of chronic obstructive…
The Ohio-based PAO Group (PAOG) is one step closer to moving RespRX to market for the treatment of chronic obstructive…
A study out of St. Michael’s Hospital in Toronto has found prescription synthetic cannabinoids are linked to a 64-percent increase…